Clinical Trial Update: Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating activated T cells armed with a GD2 bispecific antibody to treat disseminated or recurrent neuroblastoma and osteosarcoma in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• Activated T Cells armed with GD2 Bispecific Antibody

Snippet

Sponsor: University of Virginia | Conditions: Disseminated Neuroblastoma, Recurrent Neuroblastoma | Phase 1, Phase 2 | Status: UNKNOWN